Novartis’ troubles over the Zolgensma data manipulation incident show no sign of lessening. The company is on the defensive again after it emerged a senior manager sold almost $1 million worth ...

The pharmaceutical company says it will continue to operate its production facility near Research Triangle Park.

Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. Along with Zolgensma – which made its debut in 2019 – Biogen has had ...

In a statement to ProPublica, Novartis said Zolgensma’s price reflects its benefits to children with SMA and to society more broadly. “Zolgensma is consistently priced based on the value it ...

The company uses the facility to manufacture its spinal muscular atrophy gene therapy, called Zolgensma. Novartis-owned firm picks Durham over Illinois, Ireland for 200 jobs Multibillion-dollar ...

Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

Zolgensma, though, is injected into the veins, and is only cleared for use in patients under two years of age. Novartis has spent years trying to show OAV101, which is shot right into the spine ...

Novartis' drug segment is poised for steady ... (hidradenitis suppurativa in 2023), spinal muscular atrophy drug Zolgensma (intrathecal data in 2024), and cardiovascular drug Leqvio (outcomes ...

Novartis’ Durham facility produces Zolgensma, which treats spinal muscular atrophy, an inherited fatal disorder often referred to as SMA. In 2019, the Food and Drug Administration approved ...